CellPro Ceprate SC Injunction And $7 Mil. Fine Upheld By U.S. Appeals Court
This article was originally published in The Gray Sheet
CellPro plans to establish a European facility to provide the antibody used in its Ceprate SC stem cell selection technology following an Aug. 11 decision by the U.S. Court of Appeals for the Federal Circuit to uphold a partial injunction and $7 mil. fine handed down as part of a patent infringement ruling entered against CellPro in March 1997.
You may also be interested in...ï»¿
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.